Retatrutide vs tirzepatide which is better? Compare weight loss, safety, dosing, and FDA status to see which option fits your situation in the US today.
Tirzepatide (sold as Zepbound and Mounjaro) is the better choice for most people today because it is FDA-approved, widely prescribed, and supported by large phase 3 trials. Retatrutide has shown greater average weight loss in a mid-stage trial, but it remains investigational, so it cannot be legally prescribed or purchased in the United States. Retatrutide may be the more potent molecule on paper, while tirzepatide is the more proven and practical option right now.
At a Glance: Retatrutide vs Tirzepatide
Both are once-weekly injectable medications developed by Eli Lilly, and both target gut-hormone receptors that regulate appetite and blood sugar. The differences that matter most to patients are approval status, the amount of human safety data available, and how much weight each drug helped people lose in trials.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | Triple agonist: GIP, GLP-1, and glucagon | Dual agonist: GIP and GLP-1 |
| FDA status | Investigational; not approved for any use | Approved (Zepbound for weight management, Mounjaro for type 2 diabetes) |
| Average weight loss in trials | About 24% at 48 weeks (12 mg, phase 2) | About 21% at 72 weeks (15 mg, phase 3) |
| Doses studied | 1 mg to 12 mg weekly | 2.5 mg to 15 mg weekly |
| Safety database | One phase 2 trial; phase 3 ongoing | Multiple large phase 3 trials |
| How to get it | Clinical trials only | Prescription from a licensed clinician |
How the Two Drugs Work Differently
Tirzepatide activates two hormones: GIP and GLP-1. GLP-1 slows stomach emptying and reduces appetite, while GIP appears to improve how the body handles insulin and fat. That dual action is a big part of why tirzepatide outperformed semaglutide on weight loss in its clinical programs. If you are weighing older options, tirzepatide vs semaglutide which is better for weight loss covers that head-to-head question in detail.
Retatrutide adds a third target: the glucagon receptor. Glucagon is usually associated with raising blood sugar, but when it is combined with GLP-1 and GIP activity, it appears to increase energy expenditure, meaning the number of calories the body burns at rest. Researchers believe that third pathway is what pushes weight loss higher.
More receptors do not automatically mean a better medication. The glucagon component is also the reason investigators watched heart rate and liver enzymes closely during retatrutide's phase 2 trial.
Which One Produces More Weight Loss?
On average, retatrutide produced more weight loss than tirzepatide in their respective trials, but those trials were never designed to be compared directly.
| Drug | Trial phase | Dose | Treatment length | Average weight loss |
|---|---|---|---|---|
| Retatrutide | Phase 2 | 12 mg weekly | 48 weeks | About 24% |
| Retatrutide | Phase 2 | 1 mg weekly | 48 weeks | About 9% |
| Tirzepatide | Phase 3 (SURMOUNT-1) | 15 mg weekly | 72 weeks | About 21% |
| Tirzepatide | Phase 3 (SURMOUNT-1) | 5 mg weekly | 72 weeks | About 15% |
Notice the dosing column. People taking retatrutide 1 mg lost less weight than people taking the lowest approved tirzepatide doses, so dose matters as much as the drug itself.
Retatrutide's phase 2 numbers also came from a much smaller group of roughly 338 participants, and early results often shrink when a drug moves into larger phase 3 testing. Until a head-to-head trial exists, the honest answer is that retatrutide looks stronger on average, not that it will be stronger for you.
Retatrutide vs Tirzepatide: Which Is Safer?
Tirzepatide has the clearer safety picture simply because far more people have taken it under medical supervision.
- Tirzepatide: Common side effects are nausea, diarrhea, vomiting, constipation, and injection-site reactions. The label carries a boxed warning about thyroid C-cell tumors seen in rodents, and it is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2.
- Retatrutide: The phase 2 trial reported similar gastrointestinal side effects, plus dose-related increases in resting heart rate and elevated liver enzymes in some participants. These findings are being tracked in ongoing phase 3 trials.
Neither drug is risk-free, and both require a clinician's oversight. What differs is how much is known: tirzepatide's risks are documented and labeled, while retatrutide's long-term risks are still being measured.
Muscle Loss and Body Composition
Rapid weight loss of any kind costs some lean mass, and that is true for both drugs. In body-composition substudies, roughly a quarter of the weight lost with these medications came from lean tissue rather than fat. The comparison of retatrutide muscle loss vs tirzepatide is hard to settle today because retatrutide's lean-mass data come from a small substudy and tirzepatide's come from larger, longer trials. Eating enough protein and doing resistance training are the two steps most often recommended to protect muscle during treatment.
Dosing, Availability, and How to Decide
Tirzepatide is titrated slowly, typically starting at 2.5 mg and increasing every four weeks up to a maximum of 15 mg weekly, to limit side effects. Retatrutide is dosed the same way inside trials, but there is no approved dosing schedule because there is no approved product.
Retatrutide cannot be prescribed in the United States. It is not sold in pharmacies, and products marketed online as research chemicals or peptides are unregulated, unverified, and sometimes mislabeled. Buying from those sources means accepting unknown purity, unknown sterility, and no legal recourse. Several other investigational molecules are in the same position, which is why questions like is mazdutide better than retatrutide and cagrilintide vs retatrutide vs tirzepatide usually end with the same advice: wait for the data and talk to a doctor.
- Tirzepatide is the better option if you need treatment now, because it is approved, prescribable, and backed by phase 3 evidence.
- Retatrutide currently leads on average weight loss, but only in phase 2 data.
- Tirzepatide wins on volume of safety evidence, not on having zero risks.
- Enrolling in a clinical trial is the only legitimate way to access retatrutide today.
Anyone considering either medication should review their health history with a licensed healthcare professional. For a deeper breakdown of the two molecules, see our guide to retatrutide vs tirzepatide: which is better.
Frequently Asked Questions
Is retatrutide better than tirzepatide for weight loss?
In separate trials, retatrutide produced greater average weight loss, about 24% at 48 weeks with 12 mg versus roughly 21% at 72 weeks with tirzepatide 15 mg. Those studies were not compared head-to-head, and retatrutide's results come from a much smaller phase 2 trial. Retatrutide is also not FDA-approved, so it is not a realistic option for most people today.
Is retatrutide safer than tirzepatide?
No. Tirzepatide has years of phase 3 safety data and an FDA-approved label, while retatrutide's safety profile comes from a single phase 2 trial. Retatrutide has been linked to dose-related increases in resting heart rate and elevated liver enzymes in some participants, and its long-term risks are still unknown.
Can I get retatrutide with a prescription in the US?
No. Retatrutide is investigational and not approved by the FDA, so it cannot be prescribed or dispensed by a pharmacy in the United States. The only legitimate way to receive it is by enrolling in a clinical trial. Products sold online as research chemicals are unregulated and may contain unknown ingredients.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.